Join RxAnte’s Josh Benner at AMCP to discuss connecting real-world evidence to value-based contracts.

Value based care doesn't exclude drugs; however, while industry-wide cost pressures and value-based care models are changing the way healthcare is delivered, the path forward for value-based prescription drug contracting remains challenging. The process of establishing these value-based contracts (VBCs) raises questions on how to identify performance measures that are agreeable to health plans and drug manufacturers alike, and how to mitigate financial and execution risk that accompanies VBCs today. Strategies informed by a transparent analytics platform and unbiased consultative services show promise in being able to transform the way these contracts are realized—and RxAnte is sharing insights into this approach at the largest gathering of managed care professionals beginning early next week.

RxAnte is excited to attend this year's AMCP Annual Meeting and participate as an exhibitor and speaker. RxAnte President and CEO Josh Benner, PharmD, ScD, is presenting on RxAnte’s experience with the challenges and opportunities of connecting real-world evidence to performance-based drug contracts between health plans and manufacturers. A panel discussion with MagellanRx’s Jeff Dunn and Harvard Pilgrim’s Jim Kenney follows.

Event Details:
How the use of Real World evidence will Drive Value/Outcomes Based Contracting, from 8am- 10:15am on Tuesday, April 24, in the Webster Room at the Westin Boston Waterfront. To talk with us about our medication adherence and drug value solutions at this year’s AMCP Annual Meeting, please visit our booth #713.